

## Special Issue

# Comorbidity and Autoimmune Connective Tissue Disorders: From Bench to Bedside

### Message from the Guest Editors

Autoimmune connective tissue disorders are often associated with one or more comorbidities such as musculoskeletal, cardiovascular, pulmonary, or gastrointestinal diseases. Although some of these associations are well known, the relationship between comorbidities, polypharmacy, and symptoms of the underlying disease burden is often unclear. In addition, the diagnosis of many comorbidities of autoimmune connective tissue disorders is usually conducted at a late stage, and thus associated with poor prognosis. With this broad research theme in mind, we welcome manuscripts from several perspectives, including basic, clinical and translational research, in order to provide important insight into the features, biomarkers and predictive factors of comorbidities in autoimmune connective tissue disorders. Studies on safety, efficacy, and recommendations for vaccination in individuals with autoimmune diseases and comorbidities are also welcome. We look forward to receiving your contributions to the Special Issue.

Dr. Francesca Wanda Rossi

---

### Guest Editors

Dr. Ilaria Mormile

Department of Translational Medical Sciences, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy

Prof. Dr. Francesca Wanda Rossi

Department of Translational Medical Sciences (DiSMET), Center for Basic and Clinical Immunology Research (CISI), WAO Center of Excellence, University of Naples Federico II, 80131 Naples, Italy

---

### Deadline for manuscript submissions

closed (31 March 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/144526](https://mdpi.com/si/144526)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).